Mazdutide

Research Phase

Mazdutide (IBI362)

Aliases
IBI362
Administration
Subcutaneous injection

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Weight Loss & Metabolism

Mazdutide's defining research application — one of the first dual GLP-1/glucagon agonists to reach real-world regulatory approval anywhere in the world.

Weight loss

Trial and real-world data from its Chinese approval show substantial weight loss, in the same range as other dual-mechanism compounds like survodutide.

Increased energy expenditure

Shares survodutide's core differentiator — glucagon receptor activation that raises calorie burn beyond what GLP-1 activation alone achieves.

Blood sugar regulation

GLP-1 receptor activation improves insulin response and blood sugar control alongside its weight-management effect.